| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Payments of contingent value rights distributions | 7,754 | 7,754 |
| Net cash (used in) provided by financing activities | -8,003 | -7,965 |
| Effect of exchange rate changes on cash | 34 | 44 |
| Net change in cash, cash equivalents, and restricted cash | -69,160 | -52,220 |
| Cash and cash equivalents at beginning of period | 214,279 | - |
| Cash and cash equivalents at end of period | 145,119 | - |
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)